[1] International drug monitoring. The role of the hospital[J].World Health Organ Tech Rep Ser, 1969,425: 5-24. [2] Rodríguez-Monguió R, Otero M J, Rovira J.Assessing the economic impact of adverse drug effects[J].Pharmacoeconomics, 2003,21(9): 623-650. [3] 孟玉芳,茅宁莹. 药物经济学在我国医药产业的应用与发展趋势[J].中国现代药物应用, 2007, 28(9): 30-31. [4] Gyllensten H, Rehnberg C, J nsson A K, et al. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey[J]. BMJ Open, 2013,3(6): e002574. [5] Lahue B J, Pyenson B, Iwasaki K, et al.National burden of preventable adverse drug events associated with inpatient injectable medications: healthcare and medical professional liability costs[J]. Am Health Drug Benefits, 2012, 5(7): 1-10. [6] 陈崇泽.140例药品不良反应报告与成本分析[J]. 中国药物警戒, 2010,7(9):561-563. [7] Powe N R, Davidoff A J, Moore R D, et al. Net costs from three perspectives of using low versus high osmolality contrast medium in diagnostic angiocardiography[J].J Am Coll Cardiol,1993, 21(7): 1701-1709. [8] 北京大学中国医药经济研究中心药品不良反应经济成本研究课题组.药品不良反应直接经济成本研究[J]. 中国药物经济学, 2007, (2): 30-35. [9] Hannan E L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations[J].JACC Cardiovasc Interv. 2008, 1(3):211-217. [10] 肖永红,侯芳,王进,等. 抗菌药物不良反应的社会与经济后果调查[J]. 中国卫生经济, 2010,29(5): 94-96. [11] 苏长海.我院因药品不良反应导致患者再入院的发生率和严重性评价[J]. 中国药房, 2011,22(22): 2080-2083. [12] Hakkarainen K M, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions-a meta-analysis[J]. PLoS One, 2012, 7(3): e33236. [13] Rottenkolber D, Schmiedl S, Rottenkolber M, et al.Adverse drug reactions in Germany: direct costs of internal medicine hospitaliz- ations[J]. Pharmacoepidemiol Drug Saf, 2011, 20(6): 626-634. [14] Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients[J]. BMJ, 2004, 329(7456): 15-19. [15] Wu C, Bell C M, Wodchis W P. Wodchis. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study[J]. Drug Saf, 2012, 35(9): 769-781. [16] Patel K J, Kedia M S, Bajpai D, et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study[J]. BMC Clin Pharmacol, 2007, 7: 8. [17] Chan A L, Lee H Y, Ho C H, et al. Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study[J]. Curr Ther Res Clin Exp, 2008, 69(2): 118-129. [18] Carrasco-Garrido P, de Andrés L A, Barrera V H, et al. Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006)[J]. BMC Health Serv Res, 2010, 10: 287. [19] Patsopoulos NA. A pragmatic view on pragmatic trials[J].Dialogues Clin Neurosci. 2011,13(2):217-224. [20] Zwarenstein M, Treweek S, Gagnier J J, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement[J]. BMJ. 2008, 337:a2390. [21] 孙世光,闰荟,王苏会,等. 药物经济学在药品不良反应评价中的应用[J]. 中国药物经济学,2010, 4(6): 36-40. |